Edkins and a century of acid suppression

Digestion

Volumn 72, Issue 2-3, 2005, Pages 129-145

  Modlin, I M ^a   Sachs, G ^b   Wright, N ^c   Kidd, M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Acid; Centenary; Edkins; Gastrin; GERD

Indexed keywords

AMOXICILLIN; BIOLOGICAL MARKER; CIMETIDINE; CLARITHROMYCIN; FAMOTIDINE; GASTRIN; HISTAMINE AGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HISTAMINE RECEPTOR; LANSOPRAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PICOPRAZOLE; PROTON PUMP; PROTON PUMP INHIBITOR; PYRIDINE 2 THIOACETAMIDE; RABEPRAZOLE; RANITIDINE; SUCRALFATE; THIOACETAMIDE DERIVATIVE; TIMOPRAZOLE; UNCLASSIFIED DRUG;

BARRETT ESOPHAGUS; CLINICAL TRIAL; DRUG MECHANISM; DRUG SYNTHESIS; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HORMONAL REGULATION; HUMAN; LAPAROSCOPY; MEDICAL RESEARCH; NONHUMAN; PEPTIC ULCER; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STOMACH ACID; STOMACH ACID SECRETION; STOMACH FUNCTION; STOMACH PH; UNITED KINGDOM; ZOLLINGER ELLISON SYNDROME;

ANIMALS; ANTI-ULCER AGENTS; ENGLAND; GASTRIC ACID; GASTRINS; GASTROINTESTINAL TRACT; HISTORY, 20TH CENTURY; HUMANS; PEPTIC ULCER; PORTRAITS;

EID: 27144496393     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088368     Document Type: Review

References (60)

1. Modlin IM, Sachs G: Acid-Related Diseases - Biology and Treatment, ed 2. Philadelphia, Lippincott, 2004, pp 1-522.
2. Modlin IM, Kidd M, Marks IN, Tang LH: The pivotal role of J.S. Edkins in the discovery of gastrin. World J Surg 1997;21:226-234.
3. Kidd M, Modlin IM: A century of Helicobacter pylori. Paradigms lost - paradigms regained. Digestion 1998;59:1-15.
4. Modlin IM, Kidd M, Farhadi J: Bayliss and Starling and the nascence of endocrinology. Regul Pept 2000;25:109-123.
5. Gregory RA, Tracy HJ: Isolation of two 'big gastrins' from Zollinger-Ellison tumour tissue. Lancet 1972;ii:797-799.
6. McGuigan JE: Antibodies to the carboxyl-terminal tetrapeptide of gastrin. Gastroenterology 1967;53:697-705.
7. Kidd M, Modlin IM, Tang LH: Gastrin and the enterochromaffin-like cell: an acid update. Dig Surg 1998;15:209-217.
8. Sachs G, Zeng N, Prinz C: Physiology of isolated gastric endocrine cells. Annu Rev Physiol 1997;59:243-256.
9. Prinz C, Scott DR, Hurwitz D, Helander HF, Sachs G: Gastrin effects on isolated rat enterochromaffin-like cells in primary culture. Am J Physiol 1994;267:G663-G675.
10. Ash AS. Schild HO: Receptors mediating some actions of histamine. Br J Pharmacol 1966;27:427-439.
11. Molinder HK: The development of cimetidine: 1964-1976. A human story. J Clin Gastroenterol 1994;19:248-254.
12. 2 receptors. Nature 1972;236:385-390.
13. Sewing KF, Harms P, Schulz G, Hannemann H: Effect of substituted benzimidazoles on acid secretion in isolated and enriched guinea pig parietal cells. Gut 1983;24:557-560.
14. Wallmark B, Lorentzon P, Larsson H: The mechanism of action of omeprazole - a survey of its inhibitory actions in vitro. Scand J Gastroenterol Suppl 1985;108:37-51.
15. +-ATPase in vivo. Biochem Pharmacol 2004;68:2117-2127.
16. +-ATPase by proton pump inhibitors. J Am Chem Soc 2004;126:7800-7811.
17. Gillessen A, Beil W, Modlin IM, Gatz G, Hole U: 40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004;38:332-340.
18. Vagin O, Munson K, Denevich S, Sachs G: Inhibition kinetics of the gastric H,K-ATPase by K-competitive inhibitor SCH28080 as a tool for investigating the luminal ion pathway. Ann NY Acad Sci 2003;986:111-115.
19. Modlin IM, Moss SF, Kidd M, Lye KD: Gastroesophageal reflux disease: then and now. J Clin Gastroenterol 2004;38:390-402.
20. Armstrong D, Monnikes H, Bardhan KD, Stanghellini V: The construction of a new evaluative GERD questionnaire - methods and state of the art. Digestion 2004;70:71-78.
21. Shaker R: Nighttime GERD: clinical implications and therapeutic challenges. Best Pract Res Clin Gastroenterol 2004;18(suppl):31-38.
22. Bautista J, Fullerton H, Briseno M, Cui H, Fass R: The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain - a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 2004;19:1123-1130.
23. Numans ME, Lau J, de Wit NJ, Bonis PA: Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004;140:518-527.
24. Kahrilas PJ, Shi G, Manka M, Joehl RJ: Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000;118:688-695.
25. Koelz HR, Blum AL, Modlin IM: Costs of GERD: facts and fiction. Gastroenterology 2003;125:981-982.
26. Spechler SJ: Clinical practice. Barrett's esophagus. N Engl J Med 2002;346:836-842.
27. Spechler SJ: The natural history of dysplasia and cancer in esophagitis and Barrett esophagus. J Clin Gastroenterol 2003;36(suppl):S2-S5, S26-S28.
28. Spechler SJ: Should patients with GERD be screened once at least for Barrett's epithelium? A balancing view: To screen or not to screen: scoping out the issues. Am J Gastroenterol 2004;99:2295-2296.
29. Marshall JK, Collins SM, Gafni A: Prediction of resource utilization and case cost for acute nonvariceal upper gastrointestinal hemorrhage at a Canadian community hospital. Am J Gastroenterol 1999;94:1841-1846.
30. Barkun A, Sabbah S, Enns R, Armstrong D, Gregor J, Fedorak RN, Rahme E, Toubouti Y, Martel M, Chiba N, Fallone CA: The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004;99:1238-1246.
31. Jiranek GC, Kozarek RA: A cost-effective approach to the patient with peptic ulcer bleeding. Surg Clin North Am 1996;76:83-103.
32. Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J: The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors. Gastrointest Endosc 1981;27:80-93.
33. Blatchford O, Davidson LA, Murray WR, Blatchford M, Pell J: Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ 1997;315:510-514.
34. Allen R, Dykes P: A study of the factors influencing mortality rates from gastrointestinal hemorrhage. Q J Med 1976;45:533-550.
35. Chung CS: Surgery and gastrointestinal bleeding. Gastrointest Endosc Clin N Am 1997;7:687-701.
36. Marshall JK, Collins SM, Gafni A: Resource utilization for bleeding peptic ulcer disease: The Ontario Gastrointestinal Bleeding Study (abstract). Can J Gastroenterol 1998;12(suppl A):33A.
37. Rockall TA, Logan RF, Devlin HB, Northfield TC: Influencing the practice and outcome in acute upper gastrointestinal haemorrhage. Steering Committee of the National Audit of Acute Upper Gastrointestinal Haemorrhage. Gut 1997;41:606-611.
38. Cooper GS, Chak A, Way LE, Hammar PJ, Harper DL, Rosenthal GE: Early endoscopy in upper gastrointestinal hemorrhage: associations with recurrent bleeding, surgery, and length of hospital stay. Gastrointest Endosc 1999;49:145-152.
39. Laine L, Peterson WL: Bleeding peptic ulcer. N Engl J Med 1994;331:717-727.
40. Patchett S, Enright H, Afdhal N, O'Connell W, O'Donoghue D: Clot lysis by gastric juice: an in vitro study. Gut 1989;30:1704-1707.
41. Green FW Jr, Kaplan MM, Curtis LE, Levine PH: Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978;74:38-43.
42. 2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 1985;313:660-666.
43. 2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001;15:917-926.
44. Zed PJ, Loewen PS, Slavik RS, Marra CA: Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001;35:1528-1534.
45. Barkun A, Bardou M, Marshall JK: Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003;139:843-857.
46. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W, Metz DC: Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000;118:696-704.
47. Barkun AN: The role of intravenous proton pump inhibitors in the modern management of nonvariceal upper gastrointestinal bleeding. Drugs Today (Barc) 2003;39(suppl A):3-10.
48. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun A: High-dose proton pump inhibition decrease both re-bleeding and mortality in high-risk patients with acute peptic ulcer bleeding. A series of meta-analyses (abstract W1078). Gastroenterology 2003;123:A625.
49. Brunner G, Luna P, Hartmann M, Wurst W: Optimizing the intragastric pH as a supportive therapy in upper gastrointestinal bleeding. Yale J Biol Med 1996;69:225-231.
50. 2-antagonists for treatment of gastrointestinal bleeding. Ann Pharmacother 2003;37:433-437.
51. Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY: A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998;158:54-58.
52. Villanueva C, Balanzo J, Torras X, Sainz S, Soriano G, Gonzalez D, Vilardell F: Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study. Endoscopy 1995;27:308-312.
53. Coraggjo F, Rotondano G, Marmo R, Balzanelli MG, Catalano A, Clemente F, Moccia F, Parola PC: Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Eur J Gastroenterol Hepatol 1998;10:673-676.
54. Tseng GY, Lin HJ, Lin HY, Perng CL, Lee FY, Lo WC, Chang FY, Lee SD: The influence of intravenous omeprazole on intragastric pH and outcomes in patients with peptic ulcer bleeding after successful endoscopic therapy - a prospective randomized comparative trial. Hepatogastroenterology 1999;46:2183-2188.
55. Hsu PI, Lo GH, Lo CC, Lin CK, Chan HH, Wu CJ, Shie CB, Tsai PM, Wu DC, Wang WM, Lai KH: Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers. World J Gastroenterol 2004;10:3666-3669.
56. 2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002;16:1137-1142.
57. Sachs G, Weeks DL, Melchers K, Scott DR: The gastric biology of Helicobacter pylori. Annu Rev Physiol 2003;65:349-369.
58. Suerbaum S Michetti P: Helicobacter infection. N Engl J Med 2002;347:1175-1186.
59. Basset C, Holton J, Gatta L, Ricci C, Bernabucci V, Liuzzi G, Vaira D: Helicobacter pylori infection: anything new should we know? Aliment Pharmacol Ther 2004;20(suppl 2):31-41.
60. Megraud F: H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-1384.